Focal
This article was originally published in The Gray Sheet
Executive Summary
Equity investment of $5 mil. from Genzyme Surgical Products is the second of four installments to be received by Focal under an October 1999, $20 mil. commitment. In exchange, Genzyme gains exclusive North American marketing and distribution rights to Focal's FocalSeal-L lung surgery sealant. A PMA for the device is slated for review by FDA's General and Plastic Surgery Devices Advisory Panel on May 8. The funds will be used for the U.S. launch of the product and development of additional sealant product applications